BiotechTube

Olorofim + AmBisome®

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Invasive Aspergillosis

Conditions

Invasive Aspergillosis

Trial Timeline

Mar 31, 2022 → Nov 1, 2026

NCT ID
NCT05101187

About Olorofim + AmBisome®

Olorofim + AmBisome® is a phase 3 stage product being developed by Shionogi for Invasive Aspergillosis. The current trial status is active. This product is registered under clinical trial identifier NCT05101187. Target conditions include Invasive Aspergillosis.

What happened to similar drugs?

10 of 20 similar drugs in Invasive Aspergillosis were approved

Approved (10) Terminated (2) Active (9)
✅MicafunginAstellas PharmaApproved
✅caspofunginMerckApproved
✅SOC +Posaconazole 18 MG/ML (milligram/milliliter)MerckApproved
✅Caspofungin + Normal SalineMerckApproved
✅Ambisome + caspofunginGilead SciencesApproved
✅13-valent Pneumococcal conjugate vaccinePfizerApproved
✅voriconazolePfizerApproved

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05101187Phase 3Active

Competing Products

20 competing products in Invasive Aspergillosis

See all competitors
ProductCompanyStageHype Score
BSG005Alkem LaboratoriesPhase 1/2
39
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
31
Trastuzumab deruxtecan + DurvalumabDaiichi SankyoPhase 2
42
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
40
Micafungin + fluconazoleAstellas PharmaPhase 3
40
MicafunginAstellas PharmaPre-clinical
26
Micafungin (Mycamine)Astellas PharmaPhase 1
29
Pudexacianinium chlorideAstellas PharmaPhase 2
35
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
42
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
42
Isavuconazonium sulfate + Voriconazole + PosaconazoleAstellas PharmaPre-clinical
26
Pembrolizumab + Enfortumab VedotinAstellas PharmaPhase 3
44
Isavuconazonium sulfate + Isavuconazonium sulfateAstellas PharmaPhase 2
35
Micafungin + Systemic antifungal therapyAstellas PharmaPhase 2
27
MicafunginAstellas PharmaPre-clinical
26
Micafungin + PlaceboAstellas PharmaPhase 3
32
MicafunginAstellas PharmaApproved
35
Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel + Epirubicin or doxorubicin, cyclophosphamide, paclitaxelJiangsu Hengrui MedicinePhase 3
44
SHR-A1811 + Trastuzumab EmtansineJiangsu Hengrui MedicinePhase 3
47
Herombopag tablets + Herombopag placebo tabletsJiangsu Hengrui MedicinePhase 3
47